Prodrug Design

Prodrug design deliberately masks an active compound's pharmacologically essential but pharmacokinetically problematic functional group with a chemically...

Prodrug design deliberately masks an active compound's pharmacologically essential but pharmacokinetically problematic functional group with a chemically labile promoiety that is enzymatically or chemically cleaved in vivo to regenerate the active parent compound following administration, offering a route to overcoming specific pharmacokinetic liabilities — poor aqueous solubility, inadequate membrane permeability, rapid presystemic metabolism, or unacceptable taste or local irritation — without altering the fundamental pharmacophore responsible for biological activity. Common prodrug strategies include ester prodrugs of a poorly permeable carboxylic acid or alcohol-bearing parent compound, cleaved by ubiquitous esterase enzymes following absorption, and phosphate ester prodrugs used to improve the aqueous solubility of a poorly water-soluble parent compound intended for intravenous administration; prodrug design is typically deployed as a targeted solution to a specific, well-characterised pharmacokinetic liability identified during ADMET profiling, rather than as a routine or default optimization strategy.